These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 21540460)

  • 1. Prophylactic transfer of BCR-ABL-, PR1-, and WT1-reactive donor T cells after T cell-depleted allogeneic hematopoietic cell transplantation in patients with chronic myeloid leukemia.
    Bornhäuser M; Thiede C; Platzbecker U; Kiani A; Oelschlaegel U; Babatz J; Lehmann D; Hölig K; Radke J; Tuve S; Wermke M; Wehner R; Jähnisch H; Bachmann MP; Rieber EP; Schetelig J; Ehninger G; Schmitz M
    Blood; 2011 Jun; 117(26):7174-84. PubMed ID: 21540460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dendritic cells stimulate the expansion of bcr-abl specific CD8+ T cells with cytotoxic activity against leukemic cells from patients with chronic myeloid leukemia.
    Nieda M; Nicol A; Kikuchi A; Kashiwase K; Taylor K; Suzuki K; Tadokoro K; Juji T
    Blood; 1998 Feb; 91(3):977-83. PubMed ID: 9446659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ex vivo characterization of multiepitopic tumor-specific CD8 T cells in patients with chronic myeloid leukemia: implications for vaccine development and adoptive cellular immunotherapy.
    Gannagé M; Abel M; Michallet AS; Delluc S; Lambert M; Giraudier S; Kratzer R; Niedermann G; Saveanu L; Guilhot F; Camoin L; Varet B; Buzyn A; Caillat-Zucman S
    J Immunol; 2005 Jun; 174(12):8210-8. PubMed ID: 15944330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation.
    Giralt S; Hester J; Huh Y; Hirsch-Ginsberg C; Rondón G; Seong D; Lee M; Gajewski J; Van Besien K; Khouri I; Mehra R; Przepiorka D; Körbling M; Talpaz M; Kantarjian H; Fischer H; Deisseroth A; Champlin R
    Blood; 1995 Dec; 86(11):4337-43. PubMed ID: 7492795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Graft-versus-leukemia effects of Wilms' tumor 1 protein-specific cytotoxic T lymphocytes in patients with chronic myeloid leukemia after allogeneic hematopoietic stem cell transplantation.
    Wang ZD; Li D; Huang XJ
    Chin Med J (Engl); 2010 Apr; 123(7):912-6. PubMed ID: 20497687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infusion of bcr/abl peptide-reactive donor T cells to achieve molecular remission of chronic myeloid leukemia after CD34+ selected allogeneic hematopoietic cell transplantation.
    Bornhauser M; Thiede C; Babatz J; Schetelig J; Illmer T; Kiani A; Platzbecker U; Herr W; Rieber EP; Ehninger G; Schmitz M
    Leukemia; 2006 Nov; 20(11):2055-7. PubMed ID: 16990776
    [No Abstract]   [Full Text] [Related]  

  • 7. Donor Lymphocyte Infusions for Chronic Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation: May We Predict Graft-versus-Leukemia Without Graft-versus-Host Disease?
    Radujkovic A; Guglielmi C; Bergantini S; Iacobelli S; van Biezen A; Milojkovic D; Gratwohl A; Schattenberg AV; Verdonck LF; Niederwieser DW; de Witte T; Kröger N; Olavarria E;
    Biol Blood Marrow Transplant; 2015 Jul; 21(7):1230-6. PubMed ID: 25797175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infusion of CD4+ donor lymphocytes induces the expansion of CD8+ donor T cells with cytolytic activity directed against recipient hematopoietic cells.
    Zorn E; Wang KS; Hochberg EP; Canning C; Alyea EP; Soiffer RJ; Ritz J
    Clin Cancer Res; 2002 Jul; 8(7):2052-60. PubMed ID: 12114403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Generation of bcr-abl specific cytotoxic T-lymphocytes by using dendritic cells pulsed with bcr-abl (b3a2) peptide: its applicability for donor leukocyte transfusions in marrow grafted CML patients.
    Osman Y; Takahashi M; Zheng Z; Koike T; Toba K; Liu A; Furukawa T; Aoki S; Aizawa Y
    Leukemia; 1999 Feb; 13(2):166-74. PubMed ID: 10025889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Individualized intervention guided by BCR-ABL transcript levels after HLA-identical sibling donor transplantation improves HSCT outcomes for patients with chronic myeloid leukemia.
    Huang XJ; Xu LP; Liu KY; Liu DH; Chen H; Liu YR; Chen YH; Han W; Wang Y
    Biol Blood Marrow Transplant; 2011 May; 17(5):649-56. PubMed ID: 20691800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease.
    DeAngelo DJ; Hochberg EP; Alyea EP; Longtine J; Lee S; Galinsky I; Parekkedon B; Ritz J; Antin JH; Stone RM; Soiffer RJ
    Clin Cancer Res; 2004 Aug; 10(15):5065-71. PubMed ID: 15297408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A frameshift polymorphism in P2X5 elicits an allogeneic cytotoxic T lymphocyte response associated with remission of chronic myeloid leukemia.
    de Rijke B; van Horssen-Zoetbrood A; Beekman JM; Otterud B; Maas F; Woestenenk R; Kester M; Leppert M; Schattenberg AV; de Witte T; van de Wiel-van Kemenade E; Dolstra H
    J Clin Invest; 2005 Dec; 115(12):3506-16. PubMed ID: 16322791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinct graft-versus-leukemic stem cell effects of early or delayed donor leukocyte infusions in a mouse chronic myeloid leukemia model.
    Lu YF; Gavrilescu LC; Betancur M; Lazarides K; Klingemann H; Van Etten RA
    Blood; 2012 Jan; 119(1):273-84. PubMed ID: 22072555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allogeneic stem cell transplantation for patients with chronic myeloid leukemia: risk stratified approach with a long-term follow-up.
    Zuckerman T; Katz T; Haddad N; Fineman R; Dann EJ; Avivi I; Ofran Y; Gavish I; Faibish T; Sahar D; Hertz E; Sabo E; Reisner Y; Rowe JM
    Am J Hematol; 2012 Sep; 87(9):875-9. PubMed ID: 22847303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transfer of PR1-specific T-cell clones from donor to recipient by stem cell transplantation and association with GvL activity.
    Rezvani K; Price DA; Brenchley JM; Kilical Y; Gostick E; Sconocchia G; Hansmann K; Kurlander R; Douek DC; Barrett AJ
    Cytotherapy; 2007; 9(3):245-51. PubMed ID: 17464756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early administration of donor lymphocyte infusions upon molecular relapse after allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia: a study by the Chronic Malignancies Working Party of the EBMT.
    Chalandon Y; Passweg JR; Guglielmi C; Iacobelli S; Apperley J; Schaap NP; Finke J; Robin M; Fedele R; Bron D; Yakoub-Agha I; van Biezen A; de Witte T; Kröger N; Olavarria E;
    Haematologica; 2014 Sep; 99(9):1492-8. PubMed ID: 24997146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome of transplantation of highly purified peripheral blood CD34+ cells with T-cell add-back compared with unmanipulated bone marrow or peripheral blood stem cells from HLA-identical sibling donors in patients with first chronic phase chronic myeloid leukemia.
    Elmaagacli AH; Peceny R; Steckel N; Trenschel R; Ottinger H; Grosse-Wilde H; Schaefer UW; Beelen DW
    Blood; 2003 Jan; 101(2):446-53. PubMed ID: 12393406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetically modified donor leukocyte transfusion and graft-versus-leukemia effect after allogeneic stem cell transplantation.
    Borchers S; Provasi E; Silvani A; Radrizzani M; Benati C; Dammann E; Krons A; Kontsendorn J; Schmidtke J; Kuehnau W; von Neuhoff N; Stadler M; Ciceri F; Bonini C; Ganser A; Hertenstein B; Weissinger EM
    Hum Gene Ther; 2011 Jul; 22(7):829-41. PubMed ID: 21091264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-Term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation.
    Shimoni A; Gajewski JA; Donato M; Martin T; O'Brien S; Talpaz M; Cohen A; Korbling M; Champlin R; Giralt S
    Biol Blood Marrow Transplant; 2001; 7(10):568-75. PubMed ID: 11760089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A CD4+ T cell clone selected from a CML patient after donor lymphocyte infusion recognizes BCR-ABL breakpoint peptides but not tumor cells.
    Zorn E; Orsini E; Wu CJ; Stein B; Chillemi A; Canning C; Alyea EP; Soiffer RJ; Ritz J
    Transplantation; 2001 Apr; 71(8):1131-7. PubMed ID: 11374415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.